Galectin Therapeutics Inc. (NASDAQ: GALT) Stock Information | RedChip

Galectin Therapeutics Inc. (NASDAQ: GALT) Listen to this Section


$2.17
-0.0850 ( -3.78% ) 27.3K

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Market Data


Open


$2.17

Previous close


$2.25

Volume


27.3K

Market cap


$138.59M

Day range


$2.13 - $2.28

52 week range


$1.47 - $4.27

Insider Ownership Transactions

Total Amount Purchased: -544,256.00 | $ -1,178,314.24

Date Type Amount Purchased Purchaser
2024-02-07 Sale -50000.00 FREEMAN KEVIN D
2024-02-07 Sale -50000.00 OMENN GILBERT S
2024-02-07 Sale -91000.00 LEWIS JOEL
2024-02-07 Sale -50000.00 CARSON BENJAMIN SR
2024-02-07 Sale -65000.00 CALLICUTT JACK W
2024-02-07 Sale -65000.00 Boudes Pol F
2024-02-07 Sale -50000.00 AMELIO GILBERT F
2024-02-07 Sale -50000.00 Schwartz Elissa J.
2024-02-07 Sale -50000.00 Zordani Richard A. Jr.
2024-02-07 Sale -23256.00 Uihlein Richard E

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Apr 30, 2024
4 Insider transactions 1 Apr 25, 2024
5 Other 1 Apr 25, 2024
4 Insider transactions 1 Apr 25, 2024
4 Insider transactions 1 Apr 22, 2024
4 Insider transactions 1 Apr 09, 2024
10-k Annual reports 92 Mar 29, 2024
8-k 8K-related 15 Mar 29, 2024
4 Insider transactions 1 Mar 04, 2024
3 Insider transactions 1 Feb 16, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.